Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Estimated glomerular filtration rate ≥ 50 mL/min (≥ 0.83 mL/sec).~* Currently receiving an antiretroviral regimen of DTG + ABC/3TC, or ABC/DTG/3TC FDC for ≥ 3 months prior to the screening visit.~* HIV ribonucleic acid (RNA) \< 50 copies/mL at the screening visit.~* Currently on a stable regimen for ≥ 3 months preceding the screening visit with documented plasma HIV-1 RNA \< 50 copies/mL for ≥ 3 months preceding the screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).~* Have no documented or suspected resistance to emtricitabine (FTC), tenofovir (TFV), DTG, ABC or 3TC.~Key Exclusion Criteria:~* Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance.~* Active tuberculosis infection.~* Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).~* Females who are pregnant.~* Females who are breastfeeding.~* Acute hepatitis in the 30 days prior to study entry.~* Chronic Hepatitis B Virus (HBV) infection.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blinded Phase: B/F/TAF (Type: EXPERIMENTAL): B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks
- Blinded Phase: ABC/DTG/3TC (Type: ACTIVE_COMPARATOR): ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks
- Open-Label Phase (Type: EXPERIMENTAL): At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).